

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2019

**XYNOMIC PHARMACEUTICALS HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-38120</b> (Commission File Number)	<b>83-4696467</b> (IRS Employer Identification No.)
<b>China</b> (Address of principal executive offices)		<b>200031</b> (Zip Code)

Suite 3306, K. Wah Centre, 1010 Middle Huaihai Road, Shanghai,

Registrant's telephone number including area code: **+86 21 54180212**

**Bison Capital Acquisition Corp.**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A		

**Item 7.01. Regulation Fair Disclosure**

On August 1, 2019, Xynomic Pharmaceuticals Holdings, Inc. (the "Company"), issued the attached press release (the "Press Release"), announcing that it has filed an application with the U.S. Food and Drug Administration ("U.S. FDA") seeking Fast-Track designation for its drug candidate abexinostat as a monotherapy for the treatment of relapsed or refractory follicular lymphoma ("r/r FL"). A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01(d). Financial Statements and Exhibits.**

*(d) Exhibits.*

99.1 [Press Release, dated August 1, 2019](#)

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 1, 2019

**XYNOMIC PHARMACEUTICALS HOLDINGS, INC**

By: /s/ Yinglin Mark Xu

Yinglin Mark Xu

Chairman of the Board, Chief Executive Officer,  
President and Interim Chief Financial Officer